Short-term oral oleoyl-estrone treatment increases plasma cholesterol turnover in the rat.
OBJECTIVE
Oral treatment with oleoyl-estrone induces the loss of body fat and improvement of insulin resistance. Since cholesterol levels are deeply affected by oleoyl-estrone, we investigated here whether short-term treatment affected cholesterol turnover and overall metabolite changes.


METHODS
Wistar female rats received a single oral dose of 10 mumol/kg oleoyl-estrone in 0.2 ml of sunflower oil. Groups of animals were killed at timed intervals and blood samples were taken. In a second experiment series, rats had implanted carotid and jugular cannulas and were given a single gavage of oleoyl-estrone. These rats were used for the measurement of the cholesterol turnover rate.


METHODS
Body weight change and food intake: Glucose, total and HDL-cholesterol, triacylglycerols, 3-hydroxybutyrate, nonesterified fatty acids, insulin, HOMA score in the rats of the first series. Cholesterol: Cholesterol pool changes and cholesterol turnover rates in the rats of the second series.


RESULTS
OE induced early effects, decreasing food intake, cholesterol and HDL-cholesterol levels, and increasing insulin sensitivity (HOMA score). OE also increased cholesteryl-ester turnover, and decreased circulating total cholesterol, especially esterified cholesterol pools.


CONCLUSIONS
The role of early changes in insulin sensitivity induced by oral OE cannot explain per se the deep changes in cholesterol handling, essentially a consequence of accelerated lipoprotein turnover. However, the increase in cholesteryl-ester turnover observed with OE treatment may be, at least in part, a consequence of the decrease in insulin resistance. The compounded effect of increased insulin sensitivity and accelerated lipoprotein turnover may help explain the early and marked hypocholesterolaemic effects of OE.
Cabot
C
C
Departament de Nutrició i Bromatologia, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Salas
A
A
Ferrer-Lorente
R
R
Savall
P
P
Remesar
X
X
Fernández-López
J A
JA
Esteve
M
M
Alemany
M
M
D000284:Administration, Oral; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D004334:Drug Administration Schedule; D004435:Eating / Q000502:physiology; D004970:Estrone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D009829:Oleic Acids / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar
D019440:Anti-Obesity Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D008055:Lipids; D009829:Oleic Acids; D004970:Estrone; C108709:oleoyl-estrone; D002784:Cholesterol